Literature DB >> 48347

Relative analgesic potencies of morphine and hydromorphone in postoperative pain.

D L Mahler, W H Forrest.   

Abstract

Because of discrepancies in the estimates of the relative analgesic potencies of hydromorphone and morphine, the drugs were compared in two four-point, double-blind bioassays. In the first study, hydromorphone, 1 and 2 mg, was compared with morphine, 5 and 10 mg, in 31 postoperative patients; in the second, hydromorphone, 0.5 and 1 mg, was compared with morphine, 5 and 10 mg, in 112 postoperative patients. Subjective responses to nurse-observer questions were used to quantitate analgesia for postoperative pain. Hydromorphone is more potent than commonly believed: approximately 0.9 to 1.2 mg is equianalgesic with 10 mg of morphine, with a similar incidence of side effects.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 48347     DOI: 10.1097/00000542-197505000-00021

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  12 in total

1.  Pharmacokinetics of hydromorphone after intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta).

Authors:  Kristi R Kelly; Bruno H Pypendop; Kari L Christe
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-09       Impact factor: 1.232

2.  Pharmacokinetics and behavioral effects of liposomal hydromorphone suitable for perioperative use in rhesus macaques.

Authors:  Lisa Krugner-Higby; Butch KuKanich; Brynn Schmidt; Timothy D Heath; Carolyn Brown
Journal:  Psychopharmacology (Berl)       Date:  2011-03-15       Impact factor: 4.530

3.  Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis.

Authors:  George A Davis; Anita C Rudy; Sanford M Archer; Daniel P Wermeling; Patrick J McNamara
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

4.  Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs.

Authors:  L J Smith; B KuKanich; B K Hogan; C Brown; T D Heath; L A Krugner-Higby
Journal:  J Vet Pharmacol Ther       Date:  2008-10       Impact factor: 1.786

5.  Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain.

Authors:  Joris Vandenbossche; Ute Richarz; Henry M Richards
Journal:  J Pain Res       Date:  2012-11-09       Impact factor: 3.133

6.  Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain.

Authors:  Martin E Hale; Srinivas R Nalamachu; Arif Khan; Michael Kutch
Journal:  J Pain Res       Date:  2013-05-01       Impact factor: 3.133

7.  Opioid rotation with extended-release opioids: where should we begin?

Authors:  Srinivas Nalamachu
Journal:  Int J Gen Med       Date:  2011-12-30

8.  Preclinical and Clinical Pharmacology of Hydrocodone for Chronic Pain: A Mini Review.

Authors:  Luigi Cardia; Gioacchino Calapai; Domenico Quattrone; Cristina Mondello; Vincenzo Arcoraci; Fabrizio Calapai; Carmen Mannucci; Epifanio Mondello
Journal:  Front Pharmacol       Date:  2018-10-01       Impact factor: 5.810

9.  An Open-Label Study of Sufentanil Sublingual Tablet 30 Mcg in Patients with Postoperative Pain.

Authors:  Jacob L Hutchins; David Leiman; Harold S Minkowitz; Maurice Jove; Karen P DiDonato; Pamela P Palmer
Journal:  Pain Med       Date:  2018-10-01       Impact factor: 3.750

10.  A new extended release formulation (OROS) of hydromorphone in the management of pain.

Authors:  Sharon M Weinstein
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.